PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eager Eye, a number one AI firm in digital pathology for medical analysis and Ultivue, Inc. an business chief in multiplexing instruments and novel picture evaluation options for tissue biomarker research, announce a collaborative settlement to advertise multiplexed immunofluorescence (mIF) assays and scalable AI functions to unlock spatial evaluation in medical analysis.
Ultivue develops distinctive options to be used in mIF functions, imaging and spatial phenomics. Its proprietary InSituPlex® expertise enabling improved sign to noise knowledge is designed for quick and complete exploration of biologically related targets, as much as 12-plex, with identical slide-H&E evaluation in tissue samples. This expertise combines the facility of computational pathology & spatial biology to information translational science in immuno-oncology.
Ultivue acknowledges the necessity for devoted and customized AI fashions to investigate the complexity of mIF knowledge at scale and to supply improved turn-around instances and constant readouts throughout massive cohorts “We’re trying ahead to accelerating knowledge era for biopharma prospects from mIF kits by partnering with Eager Eye. We are able to collectively assist extra scalable workflows which can permit us to satisfy rising demand in medical trials.” stated Florian Leiss, Ph.D. Vice President Digital Well being Methods at Ultivue.
Eager Eye is an AI Platform firm devoted to ship correct, standardized, and undiscovered tissue insights in analysis and medical growth utilizing Deep Studying histopathology digital picture evaluation. Its proprietary fashions devoted for spatial exploration of tumor microenvironment give entry to dependable tissue segmentation, biomarker quantification, cell inhabitants profiling, and morphological discovery.
Due to Ultivue’s pre-optimized assays, the excessive accuracy achieved for each biomarker will drastically scale back errors throughout quantification steps as phenotypes mix a number of biomarkers. As Dr. Sylvain Berlemont, Eager Eye’s founder and CEO says, “We’re thrilled to increase our software portfolio mixed with best-in-class Ultivue mIF assays to biopharma firms and CROs. This partnership will undeniably assist our prospects to completely lengthen reproducibility and scalability all through their medical analysis.”.
About Eager Eye
Eager Eye is a well being expertise firm primarily based in Paris, aiming to convey AI into each analysis laboratory, CRO and pharmaceutical firm, for the good thing about biologists, pathologists, and sufferers. Eager Eye is constructing decision-support and GCLP-compliant picture evaluation options counting on Deep Studying expertise via web-based platforms. Eager Eye strives to assist the event of recent therapies with higher, quicker, and correct analytics. Be taught extra at keeneye.ai.
Ultivue gives researchers and scientists in translational medication with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® expertise permits superior exploration and interrogation of tissue samples for precision medication analysis. These extremely customizable options coupled with our scientific consultative method strengthen and speed up biomarker discovery and drug growth applications. Be taught extra at Ultivue.com.
Sylvain Berlemont, Ph.D
CEO and Founder
Florian Leiss Ph.D
Vice President Digital Well being Methods